James M Foran

41PUBLICATIONS
161CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Jun 09, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

|Apr 06, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.

Saubia Fathima, Lior Rokach, Nour Ghosoun

|Mar 30, 2026
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Nancy Gillis, Christelle Colin-Leitzinger, Yi-Han Tang

|Mar 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Francesco Passamonti, James M Foran, Anand Tandra

|Feb 25, 2026
Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance.

Yazan Jabban, Rong He, Kurt Bessonen

|Feb 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.

Naseema Gangat, Momna Warraich, Sudhesh Kumar

Pageof 7

Frequent Collaborators

17 joint publications

Naseema Gangat

16 joint publications

Talha Badar

13 joint publications

Aref Al-Kali

13 joint publications

Mithun Vinod Shah